|[May 27, 2014]
Research and Markets: Competitor Analysis Report: Cancer Vaccines 2014 - Evaluation in the Field of Novel Prophylactic and Therapeutic Vaccines to Fight Cancer
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/hsj784/competitor)
has announced the addition of the "Competitor
Analysis: Cancer Vaccines" report to their offering.
The present Competitive Intelligence report about Cancer Vaccines
provides a competitor evaluation in the field of novel prophylactic and
therapeutic vaccines to fight cancer as of March 2014. Purchase of the
downloadable pdf report includes a 6-month online access to the data of
the report and any updates since the publication date. Credentials to
access the database will be sent by e-mail and allow online work with
the project data to printor export an individual report.
Projects are listed according to their main antigenic constituents:
peptides, recombinant proteins, idiotype antibody, DNA (plasmid,
expression vector), RNA, virus-like particles (VLP), dendritic cells,
tumor cells (tumor cell lines), microorganism-based and others.
Of the 140 clinical stage cancer vaccines, three were approved and are
commercialized in the major pharmaceutical markets with combined 2013
sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical
stage cancer vaccines, followed by dendritic cell and tumor cell
(line)-based cancer vaccines with each contributing 15% to the clinical
cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out
17% of the clinical portfolio.
The report includes a compilation of currently active projects in
research and development for prophylaxis and therapy of cancer. In
addition, the report lists company-specific R&D pipelines of cancer
Competitor projects are listed in a tabular format providing
Target (News - Alert) / Mechanism of Action
Class of Compound
Additional comments with a hyperlink leading to the source of
For more information visit http://www.researchandmarkets.com/research/hsj784/competitor
[ InfoTech Spotlight's Homepage ]